The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Assessment of Alpha-synuclein Aggregation Inhibitor ASN121151 as a Potential New Treatment for Parkinson’s Disease
Study Rationale: Genetic defects in the gene encoding alpha-synuclein cause the protein to aggregate in the brains of people with a familial form of Parkinson’s disease (PD). We have developed a novel...
-
ASAP CRN 2025 RFA Scientific Track, 2026Defining Functional Heterogeneity Within the Subthalamic Area and Its Relevance for Psychiatric Symptoms of PD
Study Rationale:
Anxiety, depression, reduced motivation, and impaired cognition are common symptoms in Parkinson’s disease (PD), often occurring early in its course, before...
-
ASAP CRN 2025 RFA Scientific Track, 2026Defining Separate Rewarding and Aversive Dopaminergic Circuits and Their Role in Parkinson's Disease Associated Pain
Study Rationale:
Parkinson’s disease (PD) has traditionally been defined by people having trouble moving — walking, standing up, etc., but non-movement related symptoms...
-
Rapid Response Innovation Awards, 2008A Randomized, Double-Blind, Trial of Nexalin® vs. Placebo in Subjects with Early Parkinson's Disease
Objective/Rationale:
While the oral medications to treat PD are often quite effective in treating the physical symptoms (motor symptoms) such as tremor and stiffness, they may be associated with side... -
Rapid Response Innovation Awards, 2008Effects of noradrenergic or serotoninergic system lesions combined with NS lesions on rodent models of 'non-motor'-like symptoms
Objective/Rationale:
Parkinson’s disease is widely attributed to neuropathy of dopaminergic neurones in the nigrostriatal (NS) pathway. Degeneration of noradrenergic and serotonergic neurones in the... -
Fast Track, 2002Testosterone Therapy in Parkinson's disease
The University of Florida Movement Disorders Center will be following up the promising results of two preliminary studies of testosterone replacement therapy in male Parkinson's disease patients in a...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.